Navigation Links
Novocure Announces Launch of Recurrent Glioblastoma Product Website
Date:5/14/2012

site may have.

About Glioblastoma

Glioblastoma (GBM) is the most aggressive and most common form of primary brain tumor. The disease affects approximately 10,000 Americans each year.  The median overall survival time from initial diagnosis is 15 months with optimal treatment, and median survival from the time of tumor recurrence is only 3-5 months without additional effective treatment.  The disease is widely recognized as one of the deadliest forms of cancer.

About the NovoTTF™-100A 

The NovoTTF™-100A is a portable, non-invasive medical device designed for continuous use throughout the day by the patient.  The device has been shown in both in vitro and in vivo studies to slow and reverse tumor growth by inhibiting mitosis, the process by which cells divide and replicate.  The NovoTTF™-100A device, which weighs about six pounds (three kilograms), creates a low intensity, alternating electric field within the tumor that exerts physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death prior to division.  In patients with recurrent GBM brain tumors, the device has shown clinical efficacy comparable to that of active chemotherapies with better quality of life and without many of the side effects of chemotherapy.  The NovoTTF™-100A has received marketing approval in the US and is a CE Marked device that is cleared for sale in Europe.

Approved Indication

The US Food and Drug Administration (FDA) approved the NovoTTF-100A System in April 2011 for use as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM), following histologically– or radiologically-confirmed recurrence in the supra-tentorial region of the brain after receiving chemotherapy.  The device is intended to be used as monotherapy, a
'/>"/>

SOURCE Novocure
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. 3SBio Inc. Announces Unaudited First Quarter 2012 Results
2. Algae.Tec Announces Commencement of Australian Advanced Biofuels Facility Commissioning
3. Phalanx Biotech Group Announces CytoOneArray®, a Targeted Chromosomal Microarray
4. Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences
5. Ariosa Diagnostics Announces Nationwide Launch of the Harmony™ Prenatal Test Through LabCorp
6. PDL BioPharma Announces First Quarter 2012 Financial Results
7. BioRestorative Therapies Announces Next Generation of Stem Cell Disc Delivery Device
8. JS Genetics announces launch of XCAT-KS, a bloodless, cheek swab test for the diagnosis of Klinefelter syndrome and other Male sex chromosome aneuploidies
9. MiMedx Group Announces Record First Quarter Results
10. AnaptysBio Announces Antibody Discovery Partnership With Gilead Sciences
11. China Cord Blood Corporation Announces Completion of $65 Million Convertible Debt Financing with KKR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Convey Computer , the leader in ... State University won first place in the 2014 ... the team’s solution achieved the highest overall performance in ... place finisher. , Experts from all segments of the ... challenge, using a variety of design tools, hardware and ...
(Date:10/20/2014)... , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... Horovitz , Ph.D., from its board of directors effective on ... August 2003, and served as its chairman from June 2006 ... the Nominating and Corporate Governance and Audit Committees of the ... than a decade of dedicated service to GenVec, and its ...
(Date:10/20/2014)... 20, 2014 Local veterinary surgeon, Dr. ... investigational study of donor stem cells for dogs with ... therapy and has performed clinical stem cell therapy for ... to determine if a single injection of donor stem ... help reduce pain and inflammation in the treated joints. ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 The ... bromine market in Asia-Pacific with analysis and forecast ... the Asia Pacific Bromine Market report, to get ... also provides a glimpse of the segmentation in ... various tables and figures. , http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3
... with drug-eluting,stents must take a combination of aspirin ... year, and possibly longer, after stent,implantation. This is ... today in the journals of the Society for ... (ACC), and,American Heart Association (AHA). To access the ...
... Oral Presentation of the US Oncology Adjuvant Trial ... Symposium Showed Taxotere(R) and Cyclophosphamide ... SAN ANTONIO, Dec. 13 Results presented ... (SABCS) showed that for,women with early stage breast ...
... the premier,online community for the medical device ... edition of the US Device(TM) Hotbed,Campaign. DeviceSpace.com ... event, company and other valuable information specific ... The US Device(TM),Hotbed campaign features both a ...
Cached Biology Technology:PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents 2PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents 3PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents 4Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 2Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 3Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 4Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 5DeviceSpace.com Launches Marketing Campaign for US Medical Device Industry 2
(Date:10/18/2014)... genetic conditions, a certain type of exome sequencing method ... traditional molecular diagnostic methods, according to a study appearing ... to coincide with the American Society of Human Genetics ... region of the genome (the complete set of genes ... has been rapidly applied in research settings and recent ...
(Date:10/16/2014)... Cancer constantly wages war on the human body. ... a stalemate. In pancreatic cancer, this stalemate—known as ... becoming aggressively malignant, a phenomena that is poorly ... in the laboratory of Salvatore Torquato, a Professor ... the conditions surrounding tumor dormancy and the switch ...
(Date:10/16/2014)... respiratory tract infections and worldwide claims the lives ... and Ghent University have succeeded in developing a ... infection. , Xavier Saelens (VIB/UGent): "We discovered ... for the development of a novel approach to ... in numerous small children and elderly people." , ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Modeling tumor dormancy 2New perspectives for development of an RSV vaccine 2
... the body regulates blood pressure in response to daily ... helping people whose pressure is out of control. ... pressure is not controlled despite the best efforts of ... director of the Georgia Prevention Institute at the Medical ...
... Jabra BT530 First Product to Feature Noise Blackout(TM), ... the world leader in,innovative headset solutions, today unveiled ... Blackout(TM) reduces ambient sound,without compromising voice quality, providing ... of a natural sounding voice. The Jabra,BT530, shipping ...
... as a flavor enhancer in their food are more likely than ... though they have the same amount of physical activity and total ... Hill School of Public Health study published this month in the ... studied more than 750 Chinese men and women, aged between 40 ...
Cached Biology News:Blood pressure response to daily stress provides clues for better hypertension treatment 2Blood pressure response to daily stress provides clues for better hypertension treatment 3Blood pressure response to daily stress provides clues for better hypertension treatment 4Blood pressure response to daily stress provides clues for better hypertension treatment 5Blood pressure response to daily stress provides clues for better hypertension treatment 6GN Netcom Introduces Innovative Noise Blackout Technology 2GN Netcom Introduces Innovative Noise Blackout Technology 3UNC researchers find MSG use linked to obesity 2
Capture faint-light images without losing sensitivity or resolution. With its brand new hardware and interface design, the LAS-1000plus turns sample imaging into a simple process....
... Hamamatsu C9136 FLIM system combines the space and ... the resolution of the optical microscope to open ... short, pulsed light source for excitation, the decay ... the lifetime of the decay measured. Subtle ...
...
SDS-OutT Precipitation Reagent...
Biology Products: